Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses nature's own processes to manufacture everyday chemicals and materials—to dramatically simplify how Lenacapavir is manufactured. A novel class of HIV antiretroviral drug, Lenacapavir offers long-acting protection against HIV transmission.